PCM
SPRY icon

Pavaki Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Pavaki Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.64M Buy
579,600
+3,400
+0.6% +$29.2K 1.62% 14
2026
Q1 		$4.63M Sell
576,200
-595,800
-51% -$5.71M 1.97% 10
2025
Q4 		$13.7M Buy
+1,172,000
New +$11.4M 5.35% 5

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Pavaki Capital Management's SPRY Position: Q2 2026 in Review

Pavaki Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 0.59% in Q2 2026, buying an estimated $29.2K and bringing the position to 579,600 shares worth $4.64M. The position accounts for 1.62% of the portfolio, ranked #14.

Pavaki Capital Management first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.7M in Q4 2025. 192 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Pavaki Capital Management held 579,600 shares of ARS Pharmaceuticals worth $4.64M as of Q2 2026.
  • Pavaki Capital Management bought 3,400 ARS Pharmaceuticals shares in Q2 2026, an estimated $29.2K.
  • ARS Pharmaceuticals made up 1.62% of Pavaki Capital Management's portfolio in Q2 2026, its #14 holding.
  • Pavaki Capital Management first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management's ARS Pharmaceuticals position peaked at $13.7M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.